An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A Sandler, V Hirsh, M Reck, J von Pawel, W Akerley… - Lung Cancer, 2012 - Elsevier
BACKGROUND: Vascular endothelial growth factor (VEGF) is a key mediator of
angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent …
被引用次数：68 相关文章

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A Sandler, V Hirsh, M Reck… - Lung …, 2012 - utsouthwestern.elsevierpure.com
Background: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis.
Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on …

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A Sandler, V Hirsh, M Reck, J von Pawel… - Lung …, 2012 - lungcancerjournal.info
Background Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis.
Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on …

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

A Sandler, V Hirsh, M Reck, J von Pawel… - Lung Cancer …, 2012 - europepmc.org
Background Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis.
Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on …

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A Sandler, V Hirsh, M Reck, J von Pawel, W Akerley… - Lung Cancer, 2012 - infona.pl
Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis. Solid tumors,
including non-small cell lung cancer (NSCLC), are dependent on angiogenesis for growth …

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A Sandler, V Hirsh, M Reck… - Lung cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis.
Solid tumors, including non-small cell lung cancer (NSCLC), are dependent on …

[引用][C] An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A SANDLER, V HIRSH, M RECK, JV PAWEL… - Lung …, 2012 - pascal-francis.inist.fr
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small
cell lung cancer patients with brain metastases CNRS Inist Pascal-Francis CNRS Pascal …

[引用][C] An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

A SANDLER, V HIRSH, M RECK, JV PAWEL… - Lung cancer, 2012 - Elsevier